HOME > TOP STORIES
TOP STORIES
-
REGULATORY Market Expansion Re-Pricing to Hit Tarlige, Entresto, Verzenio; Spillover to 2 Other Meds
May 18, 2023
-
REGULATORY Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
May 17, 2023
-
REGULATORY Chuikyo OKs Listing of Omvoh, Entyvio SC, Besremi, and More; Biggest Sales Outlook for Lilly Drug
May 17, 2023
-
REGULATORY Novo’s Obesity Drug Wegovy Skips May Listing, Sobi’s Empaveli Too
May 17, 2023
-
BUSINESS Daiichi Sankyo Set to Sharpen Focus on Innovation with Generic Divestment
May 17, 2023
-
BUSINESS Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
May 16, 2023
-
BUSINESS 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
May 16, 2023
-
BUSINESS FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
May 16, 2023
-
REGULATORY G7 Health Chiefs Vow to Spur Antibiotic and Dementia Drug Development, Access to Vaccines
May 15, 2023
-
BUSINESS Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
-
REGULATORY LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
-
BUSINESS Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
May 11, 2023
-
BUSINESS Opdivo-Yervoy Shows Similar Mortality Rates in Registration Trial and RWD: Ono
May 11, 2023
-
REGULATORY LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
-
BUSINESS Over 40% of Japan Drug Makers Allow Side Jobs, MSD Has Largest 188 Staffers Tapping Option: Poll
May 9, 2023
-
REGULATORY Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
-
BUSINESS Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
May 8, 2023
-
BUSINESS Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
-
REGULATORY Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
-
ACADEMIA Lung Cancer Trial Aborted as 11 Die after Opdivo-Yervoy Therapy: NCC, JCOG
May 1, 2023
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
